Morepen Laboratories Ltd: Why Is It Outperforming Nifty 500?

Morepen Laboratories Ltd's latest quarterly results (Mar 2026) show

• PAT Growth YoY: -20.0% (stable)
• Revenue Growth YoY: +4.1%
• Operating Margin: 5.0% (volatile)

Morepen Laboratories Ltd's profit is declining with an stable trend.

• PAT Growth YoY: -20.0% (latest quarter)
• PAT Growth QoQ: -42.9% (sequential)
• 3-Year PAT CAGR: +35.0%
• Trend: Stable — consistent growth pattern

Morepen Laboratories Ltd's revenue growth trend is turning around (inflection up).

• Revenue Growth YoY: +4.1%
• Revenue Growth QoQ: +0.2% (sequential)
• 3-Year Revenue CAGR: +8.4%

Morepen Laboratories Ltd's operating margin is volatile.

• Current OPM: 5.0%
• OPM Change YoY: -4.0% basis points
• OPM Change QoQ: -5.0% basis points

Morepen Laboratories Ltd's long-term compounding rates

• 3-Year Profit CAGR: +35.0%
• 3-Year Revenue CAGR: +8.4%

Morepen Laboratories Ltd's earnings growth is stable with weakening on a sequential basis.

• YoY Acceleration: -23.7% bps
• Sequential Acceleration: -11.2% bps
• Note: YoY and QoQ trends are diverging — worth monitoring
• Margin Warning: Operating margins are under pressure

Morepen Laboratories Ltd's trailing twelve month (TTM) performance

• TTM PAT: ₹96 Cr
• TTM PAT Growth: -18.6% YoY
• TTM Revenue: ₹2,000 Cr
• TTM Revenue Growth: -0.3% YoY
• TTM Operating Margin: 7.0%

Morepen Laboratories Ltd appears significantly overvalued based on our fair value analysis.

• Valuation Signal: Significantly Overvalued
• Current PE: 39.1x
• Price-to-Book: 2.3x

Morepen Laboratories Ltd's current PE ratio is 39.1x.

• Current PE: 39.1x
• Market Cap: 2.9K Cr
• Dividend Yield: 0.38%

Morepen Laboratories Ltd's current PE is 39.1x.

• Current PE: 39.1x
• Valuation Assessment: Significantly Overvalued

Morepen Laboratories Ltd's price-to-book ratio is 2.3x.

• Price-to-Book (P/B): 2.3x
• Book Value per Share: ₹23
• Current Price: ₹53

Morepen Laboratories Ltd is rated Very Weak with a fundamental score of 17.52/100. This score is calculated from objective financial metrics

• Revenue Growth YoY: +4.1% (10% weight)
• PAT Growth YoY: -20.0% (10% weight)
• PAT Growth QoQ: -42.9% (10% weight)
• Margins stable (10% weight)

Morepen Laboratories Ltd has a debt-to-equity ratio of N/A.

• Total Debt: ₹208 Cr

Morepen Laboratories Ltd's return ratios over recent years

• FY2024: ROCE 17.0%
• FY2025: ROCE 15.0%
• FY2026: ROCE 8.0%

Morepen Laboratories Ltd's operating cash flow is positive (FY2026).

• Cash from Operations (CFO): ₹33 Cr
• Free Cash Flow (FCF): ₹-90 Cr
• CFO/PAT Ratio: 34% (weak cash conversion)

Morepen Laboratories Ltd's current dividend yield is 0.38%.

• Dividend Yield: 0.38%
• Current Price: ₹53

Morepen Laboratories Ltd's shareholding pattern (Mar 2026)

• Promoters: 35.7%
• FII (Foreign): 1.6%
• DII (Domestic): 1.3%
• Public: 61.5%

Morepen Laboratories Ltd's promoter holding has remained stable recently.

• Current Promoter Holding: 35.7% (Mar 2026)
• Previous Quarter: 35.7% (Dec 2025)
• Change: 0.00% (stable)

Morepen Laboratories Ltd has been outperforming Nifty 500 for 1 consecutive week, indicating early-stage outperformance.

Morepen Laboratories Ltd is a new entry this week — it just started outperforming Nifty 500. New entries are worth monitoring for follow-through.

Based on quantitative research signals, here is why Morepen Laboratories Ltd may be worth studying

• Cash flow is positive — CFO ₹33 Cr

Morepen Laboratories Ltd investment thesis summary:

Morepen Laboratories Ltd's forward outlook based on current data signals

• Earnings Trend: stable
• Revenue Trend: turning around (inflection up)
• Margin Trend: volatile
• Valuation: Significantly Overvalued